{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T09:10:19Z","timestamp":1780305019367,"version":"3.54.0"},"reference-count":49,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100015769","name":"Dexcom","doi-asserted-by":"crossref","award":["none"],"award-info":[{"award-number":["none"]}],"id":[{"id":"10.13039\/100015769","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Technology &amp; Therapeutics"],"published-print":{"date-parts":[[2026,6,1]]},"abstract":"<jats:p>Medicare\u2019s current coverage policy for continuous glucose monitoring (CGM) restricts their use to people with diabetes. This restriction is based on an older National Coverage Determination (NCD 40.2) that limits blood glucose testing to people with diabetes. The CGM coverage policy also requires that CGM be used only in accordance with an Food and Drug Administration (FDA) indication for its use. However, the law, regulation, and subregulatory guidance do not require such a restriction. Multiple conditions unrelated to diabetes are associated with risk of hypoglycemic events, such as postbariatric and other upper gastrointestinal surgery, glycogen storage diseases, kidney and liver failure, neuroendocrine tumors that secrete insulin, other forms of tumor-associated hyperinsulinism, and autoimmune conditions. To avoid life-threatening hypoglycemic events, these patients need access to CGM to monitor their glucose levels. Thus, the Centers for Medicare &amp; Medicaid Services should rescind NCD 40.2. The durable medical equipment Medicare administrative contractors (MACs) responsible for establishing CGM coverage policy should remove the requirement that CGM be used only in accordance with an FDA indication for its use. This would allow the MACs to extend coverage for CGM to populations at high risk for hypoglycemia, as the evidence supports such an approach.<\/jats:p>","DOI":"10.1177\/15209156251396120","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T06:42:36Z","timestamp":1763620956000},"page":"624-631","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["The Importance of Expanding Medicare Continuous Glucose Monitoring Coverage for High-Risk Hypoglycemia"],"prefix":"10.1177","volume":"28","author":[{"given":"Mary Elizabeth","family":"Patti","sequence":"first","affiliation":[{"name":"Hypoglycemia Clinic, Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazia","family":"Aleppo","sequence":"additional","affiliation":[{"name":"Diabetes Education Program, Division of Endocrinology, Metabolism and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davida","family":"Kruger","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes, Bone and Mineral Disease, Henry Ford Health, Detroit, Michigan, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol J.","family":"Levy","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes, and Metabolism, Mount Sinai Diabetes Center, Icahn School of Medicine at Mount Sinai, New York, New York, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse","family":"Bushman","sequence":"additional","affiliation":[{"name":"Dexcom, Inc., San Diego, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Umpierrez","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Metabolism, Emory University School of Medicine, Atlanta, Georgia, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolfo J.","family":"Galindo","sequence":"additional","affiliation":[{"name":"Comprehensive Diabetes Center, University of Miami, Miami, Florida, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory P.","family":"Forlenza","sequence":"additional","affiliation":[{"name":"Pediatric Endocrinology, Barbara Davis Center for Childhood Diabetes, Denver, Colorado, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders L.","family":"Carlson","sequence":"additional","affiliation":[{"name":"International Diabetes Center, Regions Hospital &amp; HealthPartners Clinics, Diabetes Education Programs, HealthPartners and Stillwater Medical Group, University of Minnesota Medical School, Minneapolis, Minnesota, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet B.","family":"McGill","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Metabolism and Lipid Research, Washington University in St. Louis School of Medicine, Saint Louis, Missouri, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-S007"},{"key":"e_1_3_2_3_2","unstructured":"Centers for Medicare & Medicaid Services. Ruling No.: CMS-1682-R. 2017. Available from: https:\/\/www.cms.gov\/regulations-and-guidance\/guidance\/rulings\/downloads\/cms1682r.pdf [Last accessed: September17 2025]."},{"key":"e_1_3_2_4_2","unstructured":"Centers for Medicare & Medicaid Services. Glucose Monitors - L33822. 2024. Available from: https:\/\/www.cms.gov\/medicare-coverage-database\/view\/lcd.aspx?lcdid=33822 [Last accessed: September17 2025]."},{"key":"e_1_3_2_5_2","unstructured":"Centers for Medicare & Medicaid Services. Glucose Monitor\u2014Policy Article. 2025. Available from: https:\/\/www.cms.gov\/medicare-coverage-database\/view\/article.aspx?articleId=52464&ver=62 [Last accessed: September17 2025]."},{"key":"e_1_3_2_6_2","unstructured":"Social Security Act. 1862(a)(1)(A). Available from: https:\/\/www.ssa.gov\/OP_Home\/ssact\/title18\/1862.htm#:\u223c:text=%5D%C2%A0(- a -)%20Notwithstanding%20any [Last accessed: September17 2025]."},{"key":"e_1_3_2_7_2","unstructured":"Centers for Medicare & Medicaid Services. Medicare Program Integrity Manual Chapter 13 Section 13.5.1 General Requirements. 2019. Available from: https:\/\/www.cms.gov\/regulations-and-guidance\/guidance\/manuals\/downloads\/pim83c13.pdf [Last accessed: September17 2025]."},{"key":"e_1_3_2_8_2","unstructured":"Diabetes Technology Access Coalition. Formal Request for LCD Reconsideration: Local Coverage Determination (LCD): Glucose Monitors (L33822). 2021. Available from: https:\/\/localcoverage.cms.gov\/attachments\/lcd\/39473_15\/cgs_lcd_l33822_reconsideration_request_09.24.2021_508_Redacted.pdf [Last accessed: September17 2025]."},{"key":"e_1_3_2_9_2","unstructured":"Centers for Medicare & Medicaid Services. Glucose Monitors - DL33822. 2022. Available from: https:\/\/localcoverage.cms.gov\/mcd_archive\/view\/lcd.aspx?lcdInfo=39473:17 [Last accessed: September17 2025]."},{"key":"e_1_3_2_10_2","unstructured":"Centers for Medicare & Medicaid Services. Response to Comments: Glucose Monitors - DL33822. 2023. Available from: https:\/\/www.cms.gov\/medicare-coverage-database\/view\/article.aspx?articleId=59330&ver=6 [Last accessed: September17 2025]."},{"key":"e_1_3_2_11_2","unstructured":"86 Federal Register 73900. 2021."},{"key":"e_1_3_2_12_2","unstructured":"Balsam JS. FDA 510(k); etter sent to Dexcom Inc. clearing the Dexcom G7 device for marketing 2024 April 23."},{"key":"e_1_3_2_13_2","unstructured":"Balsam JS. FDA 510(k) letter sent to Abbott Diabetes Care Inc. clearing the FreeStyle Libre 3 and FreeStyle Libre 2 devices for marketing. 2024."},{"key":"e_1_3_2_14_2","unstructured":"Lias CH. FDA PMA letter sent to Medtronic MiniMed approving the Guardian Connect device for marketing. 2018."},{"key":"e_1_3_2_15_2","unstructured":"Gaumer Z Bassano A Mannon M et al. Medicare Coverage Processes: An Analysis of Procedural and Resource Concerns. 2023. Available from: https:\/\/www.advamed.org\/wp-content\/uploads\/2023\/07\/AdvaMed-HMA-NC-Report-07202023.pdf [Last accessed: September17 2025]."},{"key":"e_1_3_2_16_2","unstructured":"Centers for Medicare & Medicaid Services. National Coverage Determination Dashboard. 2024. Available from: https:\/\/www.cms.gov\/files\/document\/ncddashboard2024.pdf [Last accessed: September17 2025]."},{"key":"e_1_3_2_17_2","unstructured":"89 Federal Register 65725. 2024. Available from: https:\/\/www.federalregister.gov\/d\/2024-17603\/page-65725 [Last accessed: September17 2025]."},{"key":"e_1_3_2_18_2","unstructured":"Centers for Medicare & Medicaid Services. Medicare Program Integrity Manual Chapter 13 Section 13.5.4. 2019. Available from: https:\/\/www.cms.gov\/Regulations-and-Guidance\/Guidance\/Manuals\/downloads\/pim83C13.pdf [Last accessed: September17 2025]."},{"key":"e_1_3_2_19_2","unstructured":"Centers for Medicare & Medicaid Services. Medicare Benefits Policy Manual Chapter 15 Section 110.1.C.1. 2003. Available from: https:\/\/www.cms.gov\/medicare\/prevention\/prevntiongeninfo\/downloads\/bp102c15.pdf [Last accessed: September17 2025]."},{"key":"e_1_3_2_20_2","unstructured":"CGS. Local Coverage Determinations (LCDs). 2025. Available from: https:\/\/cgsmedicare.com\/jc\/coverage\/lcdinfo.html [Last accessed: September17 2025]."},{"key":"e_1_3_2_21_2","unstructured":"Centers for Medicare & Medicaid Services. External Infusion Pumps\u2014L33794. 2024. Available from: https:\/\/www.cms.gov\/medicare-coverage-database\/view\/lcd.aspx?lcdid=33794&ver=153&contractorName=9&contractorNumber=140%7C2&lcdStatus=A&sortBy=title&bc=7 [Last accessed: September17 2025]."},{"key":"e_1_3_2_22_2","unstructured":"Centers for Medicare & Medicaid Services. Nebulizers\u2014L33370. 2024. Available from: https:\/\/www.cms.gov\/medicare-coverage-database\/view\/lcd.aspx?lcdid=33370&ver=49&contractorName=9&contractorNumber=140%7C2&lcdStatus=A&sortBy=title&bc=7 [Last accessed: September17 2025]."},{"key":"e_1_3_2_23_2","unstructured":"Centers for Medicare & Medicaid Services. Oral Antiemetic Drugs (Replacement for Intravenous Antiemetics\u2014L33827). 2025. Available from: https:\/\/www.cms.gov\/medicare-coverage-database\/view\/lcd.aspx?lcdid=33827&ver=50&contractorName=9&contractorNumber=140%7C2&lcdStatus=A&sortBy=title&bc=7 [Last accessed: September17 2025]."},{"key":"e_1_3_2_24_2","unstructured":"Centers for Medicare & Medicaid Services. Immunosuppressive Drugs\u2014L33824. 2025. Available from: https:\/\/www.cms.gov\/medicare-coverage-database\/view\/lcd.aspx?lcdid=33824&ver=38&contractorName=9&contractorNumber=140%7C2&lcdStatus=A&sortBy=title&bc=7"},{"key":"e_1_3_2_25_2","unstructured":"Centers for Medicare & Medicaid Services. 2021. Available from: https:\/\/www.cms.gov\/medicare-coverage-database\/view\/lcd.aspx?lcdid=33611&ver=25&contractorName=9&contractorNumber=140%7C2&lcdStatus=A&sortBy=title&bc=7 [Last accessed: September17 2025]."},{"key":"e_1_3_2_26_2","unstructured":"Centers for Medicare & Medicaid Services. Positive Airway Pressure (PAP) Devices for the Treatment of Chronic Obstructive Sleep Apnea. 2024. Available from: https:\/\/www.cms.gov\/medicare-coverage-database\/view\/lcd.aspx?lcdid=33718&ver=52&contractorName=9&contractorNumber=140%7C2&lcdStatus=A&sortBy=title&bc=7 [September 17 2025]."},{"key":"e_1_3_2_27_2","unstructured":"Centers for Medicare & Medicaid Services. Respiratory Assist Devices - L33800. 2024. Available from: https:\/\/www.cms.gov\/medicare-coverage-database\/view\/lcd.aspx?lcdid=33800&ver=29&contractorName=9&contractorNumber=140%7C2&lcdStatus=A&sortBy=title&bc=7"},{"key":"e_1_3_2_28_2","unstructured":"Centers for Medicare & Medicaid Services. Parenteral Nutrition\u2014L38953. 2024. Available from: https:\/\/www.cms.gov\/medicare-coverage-database\/view\/lcd.aspx?lcdid=38953&ver=16&contractorName=9&contractorNumber=140%7C2&lcdStatus=A&sortBy=title&bc=7 [Last accessed: September17 2025]."},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2023.02.012"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/cen.15169"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-S008"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1530\/EC-23-0285"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvaf106"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15096"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab323"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.4158\/EP-2019-0185"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.orcp.2015.07.003"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-016-2058-7"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-14-0821"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.36469\/jheor.2025.125886"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.00800209"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.21037\/apm-22-1422"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad641"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvab182"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199504273321707"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-97391-8"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1515\/jpem-2024-0597"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae275"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S219438"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcps2106883"}],"container-title":["Diabetes Technology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15209156251396120","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/15209156251396120","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15209156251396120","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T08:58:13Z","timestamp":1780304293000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/15209156251396120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,1]]}},"alternative-id":["10.1177\/15209156251396120"],"URL":"https:\/\/doi.org\/10.1177\/15209156251396120","relation":{},"ISSN":["1520-9156","1557-8593"],"issn-type":[{"value":"1520-9156","type":"print"},{"value":"1557-8593","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,19]]}}}